PTC Therapeutics (PTCT) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.68), $0.14 better than the analyst estimate of ($1.82). Revenue for the quarter came in at $116.7 million versus the consensus estimate of $110.5 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Tops Q1 EPS by 58c, Offers Guidance
- Amgen (AMGN) Tops Q3 EPS by 69c, Beats on Revenue; Offers FY26 Guidance
- Ouster (OUST) Misses Q3 EPS by 12c; Offer Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
